Phenotype-supported diagnosis and combined immunotherapy improve sleep and neuromuscular symptoms in seronegative Morvan syndrome
A 63-year-old man with seronegative Morvan syndrome presenting with agrypnia excitata (2-3 h/night sleep, ISI 24/28) and peripheral nerve hyperexcitability was treated with combined immunotherapy (intravenous methylprednisolone, prednisone taper, azathioprine) and symptomatic therapy (carbamazepine, melatonin). At 6 months, sleep restored to 7-8 h/night, ISI decreased from 24 to 4, MRC sum score improved from 48 to 58/60, and CK dropped from 928 to 185 U/L.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Phenotype-supported diagnosis and combined immunotherapy improve sleep and neuromuscular symptoms in seronegative Morvan syndrome The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Phenotype-supported diagnosis and combined immunotherapy improve sleep and neuromuscular symptoms in seronegative Morvan syndrome
This conclusion is most relevant to: 63-year-old Palestinian man with seronegative Morvan syndrome (complete clinical triad: neuromyotonia, agrypnia excitata, dysautonomia).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Seronegative Morvan Syndrome Presenting With Agrypnia Excitata and Peripheral Nerve Hyperexcitability: A Phenotype-Supported Diagnostic and Therapeutic Approach in a Resource-Limited Setting. (Clinical case reports, 2026) —
How It Works
The proposed biological pathway:
- ▸Immunotherapy suppresses autoimmune-mediated neuronal hyperexcitability
- ▸Carbamazepine reduces peripheral nerve hyperexcitability
- ▸Melatonin promotes sleep regulation
- ▸Result: Resolution of insomnia, neuromyotonia, and autonomic symptoms
Who Might Benefit
Evidence fit by population:
- ▸63-year-old Palestinian man with seronegative Morvan syndrome (complete clinical triad: neuromyotonia, agrypnia excitata, dysautonomia)
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Single case report with no control group
- ▸Resource-limited setting may limit generalizability to centers with biological therapies
Frequently Asked Questions
What is agrypnia excitata?▼
Agrypnia excitata is a severe insomnia phenotype characterized by near-total sleep loss, motor agitation, and autonomic hyperactivity, often seen in Morvan syndrome.
How was seronegative Morvan syndrome diagnosed in this case?▼
Diagnosis was based on the complete clinical triad (neuromyotonia, agrypnia excitata, dysautonomia), EMG findings (myokymic and neuromyotonic discharges), and exclusion of mimics, despite negative CASPR2 and LGI1 antibodies.
What treatments were effective in this patient?▼
Combined immunotherapy (methylprednisolone, prednisone, azathioprine) and symptomatic drugs (carbamazepine, melatonin) led to marked improvement in sleep, muscle strength, and CK levels at 6 months.
What is the prognosis for seronegative Morvan syndrome?▼
This case suggests that phenotype-supported diagnosis and immunotherapy can yield significant clinical improvement even in seronegative cases and resource-limited settings.
References
- 1.Taha HM, Taha KH. “Seronegative Morvan Syndrome Presenting With Agrypnia Excitata and Peripheral Nerve Hyperexcitability: A Phenotype-Supported Diagnostic and Therapeutic Approach in a Resource-Limited Setting..” Clinical case reports, 2026. PMID: 42487658 DOI: 10.1002/ccr3.73196